Clinical Cancer Research · 2019 · 48 citations · 50 references
MedicineOncologyPharmacologyChemotherapyDrug DeliveryNeuro-oncologyBlood-brain Barrier DeliveryBlood-brain Barrier PenetrationBrain TumorsCancer Drug DeliveryGlioblastomaPharmacokinetics Of Anticancer DrugsBlood-brain Barrier PermeabilityBlood-tumor Barrier PenetrationControlled Drug ReleaseCytotoxicity AssaysGlioblastoma Drug TherapyGlioma ChemotherapyPolymeric Drug ReleaseTemozolomide Therapy
Abstract Purpose: High-grade glioma (HGG) treatment is limited by the inability of otherwise potentially efficacious drugs to penetrate the blood–brain barrier. We evaluate the unique intracavity delivery mode and translational potential of a blend of poly(DL-lactic acid-co-glycolic acid; PLGA) and poly(ethylene glycol; PEG) paste combining temozolomide and etoposide to treat surgically resected HGG. Experimental Design: To prolong stability of temozolomide prodrug, combined in vitro drug release was quantitatively assessed from low pH–based PLGA/PEG using advanced analytic methods. In vitro cytotoxicity was measured against a panel of HGG cell lines and patient-derived cultures using metabolic assays. In vivo safety and efficacy was evaluated using orthotopic 9L gliosarcoma allografts, previously utilized preclinically to develop Gliadel. Results: Combined etoposide and temozolomide in vitro release (22 and 7 days, respectively) was achieved from a lactic acid–based PLGA/PEG paste, used to enhance stability of temozolomide prodrug. HGG cells from central-enhanced regions were more sensitive to each compound relative to primary lines derived from the HGG-invasive margin. Both drugs retained cytotoxic capability upon release from PLGA/PEG. In vivo studies revealed a significant overall survival benefit in postsurgery 9L orthotopic gliosarcomas, treated with intracavity delivered PLGA/PEG/temozolomide/etoposide and enhanced with adjuvant radiotherapy. Long-term survivorship was observed in over half the animals with histologic confirmation of disease-free brain. Conclusions: The significant survival benefit of intracavity chemotherapy demonstrates clinical applicability of PLGA/PEG paste-mediated delivery of temozolomide and etoposide adjuvant to radiotherapy. PLGA/PEG paste offers a future platform for combination delivery of molecular targeted compounds.
50
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Roger Stupp, Warren Mason, Martin J. van den Bent et al. · New England Journal of Medicine · 2005 · 21.6K citations · Full text
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2017 · 15K citations · Full text
Roel G.W. Verhaak, Katherine A. Hoadley, Elizabeth Purdom et al. · Cancer Cell · 2010 · 7.7K citations · Full text
The Somatic Genomic Landscape of Glioblastoma
Cameron Brennan, Roel G.W. Verhaak, Aaron McKenna et al. · Cell · 2013 · 5.2K citations · Full text